- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Alzheimer’s Disease
Volume 2012 (2012), Article ID 314185, 11 pages
Microglia in Alzheimer's Disease: It's All About Context
1Regenerative Medicine Institute Neural Program and Department of Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Steven Spielberg Building Room 345, Los Angeles, CA 90048, USA
2Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Steven Spielberg Building Room 345, Los Angeles, CA 90048, USA
3Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
Received 13 February 2012; Accepted 9 April 2012
Academic Editor: Colin Combs
Copyright © 2012 Tara M. Weitz and Terrence Town. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- H. Wisniewski, J. Wegiel, K. Wang, M. Kujawa, and B. Lach, “Ultrastructural studies of the cells forming amyloid fibers in classical plaques,” Canadian Journal of Neurological Sciences, vol. 16, no. 4, pp. 535–542, 1989.
- H. Wisniewski, J. Wegiel, K. C. Wang, and B. Lach, “Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease,” Acta Neuropathologica, vol. 84, no. 2, pp. 117–127, 1992.
- J. Frackowiak, H. Wisniewski, J. Wegiel, G. Merz, K. Iqbal, and K. C. Wang, “Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β-amyloid fibrils,” Acta Neuropathologica, vol. 84, no. 3, pp. 225–233, 1992.
- H. Wisniewski, M. Barcikowska, and E. Kida, “Phagocytosis of β/A4 amyloid fibrils of the neuritic neocortical plaques,” Acta Neuropathologica, vol. 81, no. 5, pp. 588–590, 1991.
- H. Akiyama, H. Kondo, H. Mori et al., “The amino-terminally truncated forms of amyloid β-protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients,” Neuroscience Letters, vol. 219, no. 2, pp. 115–118, 1996.
- V. W. Yong and S. Rivest, “Taking advantage of the systemic immune system to cure brain diseases,” Neuron, vol. 64, no. 1, pp. 55–60, 2009.
- K. Rezai-Zadeh, D. Gate, and T. Town, “CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?” Journal of Neuroimmune Pharmacology, vol. 4, no. 4, pp. 462–475, 2009.
- D. Gate, K. Rezai-Zadeh, D. Jodry, A. Rentsendorj, and T. Town, “Macrophages in Alzheimer's disease: the blood-borne identity,” Journal of Neural Transmission, vol. 117, no. 8, pp. 961–970, 2010.
- R. M. Ransohoff, P. Kivisäkk, and G. Kidd, “Three or more routes for leukocyte migration into the central nervous system,” Nature Reviews Immunology, vol. 3, no. 7, pp. 569–581, 2003.
- C. A. Hawkes and J. McLaurin, “Selective targeting of perivascular macrophages for clearance of β-amyloid in cerebral amyloid angiopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 4, pp. 1261–1266, 2009.
- T. Town, V. Nikolic, and J. Tan, “The microglial “activation” continuum: from innate to adaptive responses,” Journal of Neuroinflammation, vol. 2, no. 1, article 2, 2005.
- C. A. Colton, R. T. Mott, H. Sharpe, Q. Xu, W. E. Van Nostrand, and M. P. Vitek, “Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD,” Journal of Neuroinflammation, vol. 3, no. 1, article 27, 2006.
- C. A. Colton, “Heterogeneity of microglial activation in the innate immune response in the brain,” Journal of Neuroimmune Pharmacology, vol. 4, no. 4, pp. 399–418, 2009.
- C. Colton and D. Wilcock, “Assessing activation states in microglia,” CNS and Neurological Disorders, vol. 9, no. 2, pp. 174–191, 2010.
- L. Meda, M. A. Cassatella, G. I. Szendrei et al., “Activation of microglial cells by β-amyloid protein and interferon-γ,” Nature, vol. 374, no. 6523, pp. 647–650, 1995.
- J. Tan, T. Town, D. Paris et al., “Microglial activation resulting from CD40-CD40l interaction after β- amyloid stimulation,” Science, vol. 286, no. 5448, pp. 2352–2355, 1999.
- P. L. McGeer and E. McGeer, “Inflammation and the degenerative diseases of aging,” Annals of the New York Academy of Sciences, vol. 1035, no. 1, pp. 104–116, 2004.
- P. McGeer, E. McGeer, J. Rogers, and J. Sibley, “Anti-inflammatory drugs and Alzheimer disease,” The Lancet, vol. 335, no. 8696, p. 1037, 1990.
- P. McGeer and J. Rogers, “Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease,” Neurology, vol. 42, no. 2, pp. 447–449, 1992.
- P. McGeer, M. Schulzer, and E. G. McGeer, “Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies,” Neurology, vol. 47, no. 2, pp. 425–432, 1996.
- I. Mackenzie and D. Munoz, “Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging,” Neurology, vol. 50, no. 4, pp. 986–990, 1998.
- S. Weggen, J. L. Eriksen, P. Das et al., “A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity,” Nature, vol. 414, no. 6860, pp. 212–216, 2001.
- C. A. Szekely, J. E. Thorne, P. P. Zandi et al., “Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review,” Neuroepidemiology, vol. 23, no. 4, pp. 159–169, 2004.
- G. Lim, F. Yang, T. Chu et al., “Ibuprofen suppresses plaque pathology and inflammation in a mouse model for alzheimer's disease,” Journal of Neuroscience, vol. 20, no. 15, pp. 5709–5714, 2000.
- P. T. Jantzen, K. E. Connor, G. DiCarlo et al., “Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice,” The Journal of Neuroscience, vol. 22, no. 6, pp. 2246–2254, 2002.
- Q. Yan, J. Zhang, H. Liu et al., “Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease,” Journal of Neuroscience, vol. 23, no. 20, pp. 7504–7509, 2003.
- M. T. Heneka, M. Sastre, L. Dumitrescu-Ozimek et al., “Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice,” Brain, vol. 128, no. 6, pp. 1442–1453, 2005.
- D. M. Wilcock, P. T. Jantzen, Q. Li, D. Morgan, and M. N. Gordon, “Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid,” Neuroscience, vol. 144, no. 3, pp. 950–960, 2007.
- T. Kukar, M. P. Murphy, J. L. Eriksen et al., “Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production,” Nature Medicine, vol. 11, no. 5, pp. 545–550, 2005.
- J. Tan, T. Town, F. Crawford et al., “Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice,” Nature Neuroscience, vol. 5, no. 12, pp. 1288–1293, 2002.
- K. P. Townsend, T. Town, T. Mori et al., “CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid β-peptide,” European Journal of Immunology, vol. 35, no. 3, pp. 901–910, 2005.
- X. Qiao, D. J. Cummins, and S. M. Paul, “Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse,” European Journal of Neuroscience, vol. 14, no. 3, pp. 474–482, 2001.
- T. Mori, N. Koyama, G. W. Arendash, Y. Horikoshi-Sakuraba, J. Tan, and T. Town, “Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease,” GLIA, vol. 58, no. 3, pp. 300–314, 2010.
- M. Fuhrmann, T. Bittner, C. K. E. Jung et al., “Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease,” Nature Neuroscience, vol. 13, no. 4, pp. 411–413, 2010.
- S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic model of Alzheimer's Disease with plaques and tangles: intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003.
- S. Lee, N. H. Varvel, M. E. Konerth et al., “CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models,” American Journal of Pathology, vol. 177, no. 5, pp. 2549–2562, 2010.
- G. N. Patrick, L. Zukerberg, M. Nikolic, S. De La Monte, P. Dikkes, and L. H. Tsai, “Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration,” Nature, vol. 402, no. 6762, pp. 615–622, 1999.
- J. R. Sundaram, E. S. Chan, C. P. Poore, et al., “Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration,” Journal of Neuroscience, vol. 32, no. 3, pp. 1020–1034, 2012.
- T. E. Golde, “Inflammation takes on Alzheimer disease,” Nature Medicine, vol. 8, no. 9, pp. 936–938, 2002.
- A. R. Group, C. Lyketsos, J. Breitner, et al., “Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial,” Neurology, vol. 68, no. 21, pp. 1800–1808, 2007.
- B. K. Martin, C. Szekely, J. Brandt et al., “Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib,” Archives of Neurology, vol. 65, no. 7, pp. 896–905, 2008.
- P. L. McGeer and E. G. McGeer, “NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies,” Neurobiology of Aging, vol. 28, no. 5, pp. 639–647, 2007.
- J. C. Breitner, L. D. Baker, T. J. Montine et al., “Extended results of the Alzheimer's disease anti-inflammatory prevention trial,” Alzheimer's and Dementia, vol. 7, no. 4, pp. 402–411, 2011.
- C. Holmes, C. Cunningham, E. Zotova et al., “Systemic inflammation and disease progression in Alzheimer disease,” Neurology, vol. 73, no. 10, pp. 768–774, 2009.
- D. Schenk, R. Barbour, W. Dunn et al., “Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse,” Nature, vol. 400, no. 6740, pp. 173–177, 1999.
- C. Janus, J. Pearson, J. McLaurin et al., “Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease,” Nature, vol. 408, no. 6815, pp. 979–982, 2000.
- D. Morgan, D. M. Diamond, P. E. Gottschall et al., “A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease,” Nature, vol. 408, no. 6815, pp. 982–985, 2000.
- F. Bard, C. Cannon, R. Barbour et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” Nature Medicine, vol. 6, no. 8, pp. 916–919, 2000.
- E. Check, “Nerve inflammation halts trial for Alzheimer's drug,” Nature, vol. 415, no. 6871, p. 462, 2002.
- J. A. R. Nicolll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller, “Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report,” Nature Medicine, vol. 9, no. 4, pp. 448–452, 2003.
- C. Holmes, D. Boche, D. Wilkinson et al., “Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial,” The Lancet, vol. 372, no. 9634, pp. 216–223, 2008.
- E. Masliah, M. Mallory, L. Hansen et al., “Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease,” Acta Neuropathologica, vol. 83, no. 1, pp. 12–20, 1991.
- J. Tan, T. Town, T. Mori et al., “CD45 opposes β-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase,” Journal of Neuroscience, vol. 20, no. 20, pp. 7587–7594, 2000.
- Y. Zhu, H. Hou, K. Rezai-Zadeh et al., “CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice,” Journal of Neuroscience, vol. 31, no. 4, pp. 1355–1365, 2011.
- S. S. Shaftel, S. Kyrkanides, J. A. Olschowka, J. N. H. Miller, R. E. Johnson, and M. K. O'Banion, “Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology,” Journal of Clinical Investigation, vol. 117, no. 6, pp. 1595–1604, 2007.
- P. Chakrabarty, C. Ceballos-Diaz, A. Beccard et al., “IFN-γ promotes complement expression and attenuates amyloid plaque deposition in amyloid β precursor protein transgenic mice,” Journal of Immunology, vol. 184, no. 9, pp. 5333–5343, 2010.
- P. Chakrabarty, K. Jansen-West, A. Beccard et al., “Massive gliosis induced by interleukin-6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition,” FASEB Journal, vol. 24, no. 2, pp. 548–559, 2010.
- P. Chakrabarty, A. Herring, C. Ceballos-Diaz, P. Das, and T. E. Golde, “Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo,” Molecular Neurodegeneration, vol. 6, no. 1, article 16, 2011.
- G. DiCarlo, D. Wilcock, D. Henderson, M. Gordon, and D. Morgan, “Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice,” Neurobiology of Aging, vol. 22, no. 6, pp. 1007–1012, 2001.
- D. M. Wilcock, M. R. Lewis, W. E. van Nostrand et al., “Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2,” Journal of Neuroscience, vol. 28, no. 7, pp. 1537–1545, 2008.
- T. Town, V. Nikolic, and J. Tan, “The microglial “activation” continuum: from innate to adaptive responses,” Journal of Neuroinflammation, vol. 2, article 24, 2005.
- C. A. Colton, R. T. Mott, H. Sharpe, Q. Xu, W. E. van Nostrand, and M. P. Vitek, “Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD,” Journal of Neuroinflammation, vol. 3, article 27, 2006.
- C. A. Colton and D. M. Wilcock, “Assessing activation states in microglia,” CNS and Neurological Disorders, vol. 9, no. 2, pp. 174–191, 2010.
- S. A. Grathwohl, R. E. Kälin, T. Bolmont et al., “Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia,” Nature neuroscience, vol. 12, no. 11, pp. 1361–1363, 2009.
- A. K. Stalder, F. Ermini, L. Bondolfi et al., “Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice,” Journal of Neuroscience, vol. 25, no. 48, pp. 11125–11132, 2005.
- A. R. Simard, D. Soulet, G. Gowing, J. P. Julien, and S. Rivest, “Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease,” Neuron, vol. 49, no. 4, pp. 489–502, 2006.
- J. El Khoury, M. Toft, S. E. Hickman et al., “Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease,” Nature Medicine, vol. 13, no. 4, pp. 432–438, 2007.
- Y. Laouar, T. Town, D. Jeng et al., “TGF-β signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 31, pp. 10865–10870, 2008.
- T. Town, Y. Laouar, C. Pittenger et al., “Blocking TGF-β-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology,” Nature Medicine, vol. 14, no. 6, pp. 681–687, 2008.
- F. Geissmann, S. Jung, and D. R. Littman, “Blood monocytes consist of two principal subsets with distinct migratory properties,” Immunity, vol. 19, no. 1, pp. 71–82, 2003.
- C. Sunderkötter, T. Nikolic, M. J. Dillon et al., “Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response,” Journal of Immunology, vol. 172, no. 7, pp. 4410–4417, 2004.
- G. P. Lim, T. Chu, F. Yang, W. Beech, S. A. Frautschy, and G. M. Cole, “The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse,” Journal of Neuroscience, vol. 21, no. 21, pp. 8370–8377, 2001.